Literature DB >> 198120

Relationship between feline leukemia virus antigen expression and viral infectivity in blood, bone marrow, and saliva of cats.

E A Hoover, R G Olsen, L E Mathes, J P Schaller.   

Abstract

Correlation was greater than 90% between feline leukemia virus (FeLV), group-specific antigen (GSA) in leukocytes, and viral infectivity (VI) in serum or plasma from 132 cats infected with either the Rickard strain of FeLV, the Snyder-Theilen strain of feline sarcoma virus, or field strains of FeLV. Detection of GSA in blood cells was at least as sensitive as detection of VI in serum. In 45% of FeLV GSA-positive cats inoculated with FeLV-Rickard strain, VI was detected in saliva. No saliva samples from GSA-negative cats had VI. Sequential bone marrow biopsies from 34 cats inoculated with Snyder-Theilen feline sarcoma virus indicated that the correlation between FeLV GSA in bone marrow cells and blood cells was virtually 100%. FeLV GSA appeared in bone marrow leukocyte precursors 1 week before its appearance in peripheral blood leukocytes in 50% of the cats. The FeLV GSA-positive state was transient (3 to 6 weeks) in 34% of the Snyder-Theilen feline sarcoma virus-inoculated cats.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 198120

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Effects of cobra venom factor treatment on latent feline leukemia virus infection.

Authors:  E H Kraut; J L Rojko; R G Olsen; D L Tuomari
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

2.  Feline glucose-6-phosphate dehydrogenase cellular mosaicism. Application to the study of retrovirus-induced pure red cell aplasia.

Authors:  J L Abkowitz; R L Ott; J M Nakamura; L Steinmann; P J Fialkow; J W Adamson
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

3.  In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model.

Authors:  P J Polas; C L Swenson; R Sams; C M Cheney; K A Hayes; M J Tarr; G J Kociba; L E Mathes
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  Feline leukemia virus immunity induced by whole inactivated virus vaccination.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2009-10-31       Impact factor: 2.046

5.  A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A.

Authors:  Ramon Mendoza; Maria M Anderson; Julie Overbaugh
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 6.  Feline leukemia/sarcoma viruses and immunodeficiency.

Authors:  J Rojko; M Essex; Z Trainin
Journal:  Adv Vet Sci Comp Med       Date:  1988

7.  A vector expressing feline mature IL-18 fused to IL-1beta antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus.

Authors:  Lucy H O'Donovan; Elizabeth L McMonagle; Samantha Taylor; Derek Bain; Angela M Pacitti; Mathew C Golder; Michael McDonald; Linda Hanlon; David E Onions; David J Argyle; Oswald Jarrett; Lesley Nicolson
Journal:  Vaccine       Date:  2005-03-16       Impact factor: 3.641

Review 8.  Persistent viral infection. The carrier state.

Authors:  R C Povey
Journal:  Vet Clin North Am Small Anim Pract       Date:  1986-11       Impact factor: 2.093

Review 9.  The immunobiology of the feline leukemia virus.

Authors:  J L Rojko; R G Olsen
Journal:  Vet Immunol Immunopathol       Date:  1984-05       Impact factor: 2.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.